Cover Image

Cost-effectiveness analysis of infant pneumococcal vaccination with PHiD-CV in Korea

Background: Streptococcus pneumoniae and non-typeable Haemophilus influenzae (NTHi) can cause invasive pneumococcal diseases (IPD), pneumonia, and acute otitis media (AOM). Both the 10-valent pneumococcal NTHi protein D conjugate vaccine (PHiD-CV) and the 13-valent pneumococcal conjugate vaccine (PC...

Full description

Saved in:

Bibliographic Details
Main Authors:	Xu-Hao Zhang (Author), Oscar Leeuwenkamp (Author), Kyu-Bin Oh (Author), Young Eun Lee (Author), Chul-Min Kim (Author)
Format:	Book
Published:	Taylor & Francis Group, 2018-01-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Overall effectiveness of pneumococcal conjugate vaccines: An economic analysis of PHiD-CV and PCV-13 in the immunization of infants in Italy
by: Paolo Castiglia, et al.
Published: (2017)

Exploring the evidence behind the comparable impact of the pneumococcal conjugate vaccines PHiD-CV and PCV13 on overall pneumococcal disease
by: Patricia Izurieta, et al.
Published: (2022)

A 6-year safety surveillance of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in South Korea
by: Soon Min Lee, et al.
Published: (2018)

Effectiveness and impact of the 10-valent pneumococcal conjugate vaccine, PHiD-CV: review of clinical trials and post-marketing experience
by: Tomas Mrkvan, et al.
Published: (2018)

Safety profile of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV)
by: Sven Arne Silfverdal, et al.
Published: (2017)

Primary vaccination with the 10-valent pneumococcal non-typeable <it>Haemophilus influenzae </it>protein D conjugate vaccine (PHiD-CV) in infants in Mali and Nigeria: a randomized controlled trial
by: Dicko Alassane, et al.
Published: (2011)

A cost-effectiveness analysis of PHiD-CV compared to PCV13 in a national immunization program setting in Tunisia
by: Youness Lagoubi, et al.
Published: (2022)

Pneumonia hospitalizations and mortality in children 3 - 24-month-old in Nigeria from 2013 to 2020: Impact of pneumococcal conjugate vaccine ten valent (PHiD-CV-10)
by: Jalo Iliya, et al.
Published: (2023)

Immunization with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) according to different schedules in infants in South Africa: a phase III trial
by: Shabir A Madhi, et al.
Published: (2017)

Estimated public health impact of human rotavirus vaccine (HRV) and pneumococcal polysaccharide protein D-conjugate vaccine (PHiD-CV) on child morbidity and mortality in Gavi-supported countries
by: Alen Marijam, et al.
Published: (2022)

Effects of prophylactic ibuprofen and paracetamol administration on the immunogenicity and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugated vaccine (PHiD-CV) co-administered with DTPa-combined vaccines in children: An open-label, randomized, controlled, non-inferiority trial
by: Oana Falup-Pecurariu, et al.
Published: (2017)

Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South Korea
by: Min-Joo Choi, et al.
Published: (2018)

Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea
by: Hye-Young Kim, et al.
Published: (2021)

Recommendation for use of the newly introduced pneumococcal protein conjugate vaccines in Korea
by: Eun Hwa Choi, et al.
Published: (2011)

Cost-effectiveness analysis of routine 13-valent pneumococcal conjugate vaccinations in Chinese infants
by: Hua Zhou, et al.
Published: (2018)

Agreement Beyond Phi
by: Miyagawa, Shigeru
Published: (2017)

PhyGeometry: ORGANizing physiology
by: Hwee-Ming Cheng, et al.
Published: (2021)

Cost-effectiveness analysis of adult pneumococcal conjugate vaccines for pneumococcal disease in Japan
by: Shigeki Nakamura, et al.
Published: (2024)

Evaluating the costs and benefits of pneumococcal vaccination in adults
by: Barbara Rita Porchia, et al.
Published: (2017)

Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants
by: Johnna Perdrizet, et al.
Published: (2021)

A cost-effectiveness analysis of pneumococcal conjugate vaccines in infants and herd protection in older adults in Colombia
by: Jaime E. Ordóñez, et al.
Published: (2023)

PCV15, a pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease in infants and children
by: Timothy J Chapman, et al.
Published: (2024)

Is HIF-PHI the Answer to Tackle ESA Hyporesponsiveness in the Elderly?
by: Henry H. L. Wu, et al.
Published: (2022)

Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine in adults in Portugal versus "no vaccination" and versus vaccination with the 23-valent pneumococcal polysaccharide vaccine
by: Miguel Gouveia, et al.
Published: (2019)

Intel Xeon Phi Coprocessor Architecture and Tools The Guide for Application Developers /
by: Rahman, Rezaur
Published: (2013)

Intel Xeon Phi Coprocessor Architecture and Tools The Guide for Application Developers
by: Rahman, Rezaur
Published: (2013)

Intel Xeon Phi Coprocessor Architecture and Tools The Guide for Application Developers
by: Rahman, Rezaur
Published: (2013)

A systematic review of the burden of pertussis in South Korea
by: Bruce A. Mungall, et al.
Published: (2021)

Response to article by Johnna Perdrizet et al.,"Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants"
by: Jorge A. Gómez, et al.
Published: (2022)

Indirect costs of adult pneumococcal disease and the productivity-based rate of return to the 13-valent pneumococcal conjugate vaccine for adults in Turkey
by: J. P. Sevilla, et al.
Published: (2020)

A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult
by: Thundon Ngamprasertchai, et al.
Published: (2023)

Health and economic burden associated with 15-valent pneumococcal conjugate vaccine serotypes in Korea and Hong Kong
by: Salini Mohanty, et al.
Published: (2022)

Correlation between private education costs and parental depression in South Korea
by: Byeong Cheol Oh, et al.
Published: (2020)

Effect and cost-effectiveness of pneumococcal conjugate vaccination: a global modelling analysis
by: Cynthia Chen, PhD, et al.
Published: (2019)

Impact of the introduction of pneumococcal conjugate vaccine on immunization coverage among infants
by: Wei Feifei, et al.
Published: (2005)

EXPERIENCE OF IMPLEMENTATION OF THE COHORT PNEUMOCOCCAL VACCINATION PROGRAM FOR INFANTS IN ST. PETERSBURG
by: S. M. Kharit, et al.
Published: (2014)

Occupational Injury Statistics in Korea
by: Seong-Kyu Kang, et al.
Published: (2011)

Public health impact of pneumococcal conjugate vaccine infant immunization programs: assessment of invasive pneumococcal disease burden and serotype distribution
by: Patricia Izurieta, et al.
Published: (2018)

Intel Xeon Phi Coprocessor Architecture and Tools: The Guide for Application Developers
by: Rezaur Rahman
Published: (2013)

Review of vaccine effectiveness assumptions used in economic evaluations of infant pneumococcal conjugate vaccine
by: Matt Wasserman, et al.
Published: (2018)